← all works
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Asthma and respiratory diseases
- Field
- Medicine
- Canadian institutions
- McMaster UniversitySt. Joseph’s Healthcare HamiltonVancouver General Hospital
- Funders
- Wake Forest School of MedicineTeva Pharmaceutical IndustriesAstraZeneca
- Keywords
- BenralizumabMedicinePlaceboMepolizumabAsthmaExacerbationInternal medicineClinical endpointEosinophilGastroenterologyRandomized controlled trialPathology
- Has abstract in OpenAlex
- no